Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2506699 | 1.00 | CTSS (0.44) | CTSSCTSKPOLBLMNASCN9A | |
| SCHEMBL27929157 | 0.91 | POLB (0.45) | CTSSCTSKPOLBLMNASCN9A | |
| SCHEMBL12222165 | 0.91 | CTSK (0.46) | CTSSCTSKPOLBSCN9AMAPK1 | |
| SCHEMBL2508228 | 0.88 | EPHX2 (0.42) | POLBLMNAMAPK1 | |
| SCHEMBL2503898 | 0.86 | CTSK (0.43) | CTSSCTSKPOLBSCN9ATP53 | |
| SCHEMBL2503897 | 0.86 | CTSK (0.43) | CTSSCTSKPOLBSCN9ATP53 | |
| SCHEMBL2510363 | 0.83 | AAK1 (0.45) | CTSSCTSKPOLBLMNASCN9A | |
| SCHEMBL2510364 | 0.83 | AAK1 (0.45) | CTSSCTSKPOLBLMNASCN9A | |
| SCHEMBL12222740 | 0.80 | CTSS (0.43) | CTSSCTSKPOLBLMNASCN9A | |
| SCHEMBL2507744 | 0.80 | POLB (0.49) | CTSSCTSKPOLBLMNASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | CTSS 598/4885CTSK 1268/4885POLB 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.